News - Press Releases
Date: 25-01-2010
Psynova Neurotech and Bahn lab part of one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression. [read PDF file]
Date: 08-12-2009
PSYNOVA ANNOUNCES COMPANION DIAGNOSTIC COLLABORATION WITH ROCHE - Utilizing Psynova’s schizophrenia biomarker portfolio and RBM’s DiscoveryMAP™ technology -
Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of Rules-Based Medicine, Inc. (RBM), today announced an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation, and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia. [read PDF file]
Date: 20-10-2009
Milestone Triggers Additional RBM Investment in Psynova
CAMBRIDGE, England and AUSTIN, Texas – October 20, 2009 -- Psynova Neurotech Ltd. (Psynova) and Rules-Based Medicine, Inc. (RBM) today announced the discovery and characterisation of a combination of protein biomarkers demonstrating utility as an adjunctive aid in the differential diagnosis of schizophrenia. As a result of this clinical milestone, RBM has made additional investments in Psynova, and now has a controlling interest in the company. [read PDF file]
Date: 16-07-2009
Cambridge, UK (July 2009) Psynova Neurotech, a UK based CNS diagnostics company announced today that it is part of an 8 member consortium that has been awarded a €2.75million European Commission Framework 7 grant to develop minimally invasive, high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders. The consortium includes the laboratories of Dr. Sabine Bahn (University of Cambridge), Dr. Pauline Rudd (National Institute for Bioprocessing Research and Training, Dublin), Dr. Markus Leweke (Central Institute of Mental Health, Mannheim), and Dr. Matthias Rothermundt (University of Muenster) as well as 3 SMEs - EDI GmbH (Germany), Storkbio Ltd. (Estonia) and Psynova Neurotech Ltd. (UK). Pera International (UK) will help manage the 3 year project and Psynova Neurotech will be the project co-ordinator. [read PDF file]
Date: 11-06-2008
Cambridge, UK and Austin, TX (June 11 2008): Psynova Neurotech, a UK based company developing novel biomarkers to aid the diagnosis and treatment of neuropsychiatric illnesses, announced today it is partnering with Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory, to co-develop and commercialise a blood test for the diagnosis of schizophrenia. [read PDF file]
Date: 29-06-2007
Psynova Neurotech Wins Prestigious Medical Futures Award
June 2007: Psynova Neurotech is pleased to announce it is this year’s winner of The
Overall Mental Health & Neurosciences Innovation Award in the Medical Futures
Innovation Awards.
Consultant Psychiatrist, Sabine Bahn has been judged the overall winner for the Mental
Health and Neurosciences category. Her entry Psynova Neurotech - is a blood test to
diagnose mental health diseases such as depression or schizophrenia. [read PDF file]
Date: 26-04-2007
Dr George McAllister joins Psynova Neurotech Neurotech as Head of R&D
Psynova Neurotech Neurotech, a UK based company developing and exploiting novel biomarkers for Neuropsychiatric illnesses, is pleased to announce the appointment of Dr George McAllister as Head of Research and Development, effective immediately.
George has a PhD in Neuropsychiatric disorders and has amassed more than 16 years of commercial experience in this field. He has extensive experience in the areas of molecular and cell biology, neural stem cells, target identification and validation and drug discovery and screening in programmes for bipolar depression, migraine and schizophrenia. [read PDF file]
Date: 06-11-2006
Psynova Neurotech injected with a further £250k as it develops commercial potential
Psynova Neurotech Ltd, the spin-out from The University of Cambridge which focuses on the advancement and exploitation of biomarkers for neuropsychiatric disorders, has received a further £250k from investors after reaching agreed milestones.
The funding comes from Porton Capital Ltd (£200k) and Cambridge Enterprise Seed Funds (£50k) as Psynova Neurotech draws closer to developing diagnostic tests and therapeutic agents for Schizophrenia and Bipolar Disorders as well as other significant neuropsychiatric illnesses. [read PDF file]
Date: 02-10-2006
Psynova Neurotech set to turn heads at 14th Annual BioPartnering Europe Event
Psynova Neurotech - the company developing and exploiting novel biomarkers for Neuropsychiatric illnesses - will be holding a presentation at the 14th Annual BioPartnering Europe (BPE) on 8-10h October in London.
BioPartnering Europe (BPE), first held in 1993 as a partnership between the U.S. Commercial Service and Technology Vision Group LLC, aims to strengthen ties between American and European biotechnology companies. [read PDF file]
Date: 21-09-2006
Professor Christopher Lowe, "Most Entrepreneurial Scientist of the UK"
On Thursday 21st September 2006, Mr Alan Barrell, Professor of Entrepreneurship at the University of Luton and Xiamen and Entreprenuer in Residence, announced the winner of the UK competition to select and reward "The Most Entrepreneurial Scientist of the United Kingdom. [read PDF file]
Date: 27-08-2006
Psynova Neurotech announces patent deal with Cambridge University
Specialists in novel biomarkers for Neuropsychiatric illnesses, Psynova Neurotech, have obtained an option to licence a patent owned by Cambridge University Technical Services (CUTS), which protects an invention made by Psynova Neurotech co-founder Prof. Sabine Bahn. The invention relates to a method for monitoring and diagnosing psychotic disorders, including Schizophrenia. [read PDF file]
Psynova Neurotech announces additional Non-Executive Director appointment
Psynova Neurotech has announced another addition to its board in the form of Ian Ragan, as Non-Executive Director. Ian’s role will be to advise on the development and execution of Psynova Neurotech's R&D programmes and its business development activities. [read PDF file]
Psynova Neurotech steps up a gear and appoints Non-Executive Director to board
Established to commercially develop and exploit novel biomarkers for Neuropsychiatric illnesses, year old company Psynova Neurotech announced the addition of Vishal Gulati, as Non-Executive Director to its board today. [read PDF file]